STRENGTH IN NUMBERS

Strength in Numbers dedicated to my late mother Kay

Prostate cancer could be ‘transformed from killer disease to chronic illness’ for thousands of men after NHS give green light to promising drug

  • Experts say men who took the drug had 29% better chance of survival
  • Trials found drug delayed need for chemotherapy by average of 17 months 
  • Drug costs £2,734 a month and had previously been refused by NICE

Thousands of men are to benefit from a prostate cancer drug which delays the need for gruelling chemotherapy. Officials at NICE – the National Institute for Health and Care Excellence – have reversed their previous decision and recommended that enzalutamide be funded on the NHS. An estimated 5,500 men in England and Wales each year are expected to benefit from use of the drug, which slashes the risk of prostate cancer progressing. Clinical trials have shown that the treatment delays the need for chemotherapy by an average 17 months, substantially increasing quality of life for patients.

Men who took the drug at this stage also had a 29 per cent better overall chance of survival. Doctors say the treatment, which was developed by British scientists, has the potential to transform prostate cancer from a killer disease unto a chronic illness. Enzalutamide is already available if chemotherapy has failed – but cancer charities have repeatedly insisted that the drug, which is also called Xtandi, will benefit even more men if it is used before chemotherapy. Yet officials at NICE published a draft decision in June indicating it would not be approved for routine use before chemotherapy.

Click on the link to read more

http://www.dailymail.co.uk/health/article-3356254/Prostate-cancer-transformed-killer-disease-chronic-illness-thousands-men-NHS-green-light-promising-drug.html?ITO=1490&ns_mchannel=rss&ns_campaign=1490

2F49069800000578-0-image-m-60_1449849501045

The drug was found to delay the need for chemotherapy in patients for an average 17 months, increasing the quality of life for patients. (The prostate is pictured, orange, below the bladder)

Filed under: Cancer, , , ,

NHS will not offer ‘innovative’ drug to treat prostate cancer

Cancer charities are disappointed with health officials who have deemed a new and ‘innovative’ drug to treat advanced prostate cancer is not cost-effective for the NHS.

Enzalutamide is currently available on the Cancer Drugs Fund in England, which enables patients to access drugs that would not otherwise have been routinely available from the NHS. But the National Institute for Health and Care Excellence (Nice) has published draft guidance in which it says the drug has not been proven to work well enough for the price the NHS must pay for it.

The drug, also called Xtandi, is licensed to treat people with prostate cancer that has spread to other parts of the body who have not yet had chemotherapy, and in whom treatments to lower the amount of male sex hormones – which normally stop the cancer from growing and spreading – no longer work.

Click on the link to read more

http://www.itv.com/news/2015-06-11/nhs-will-not-offer-innovative-drug-to-treat-prostate-cancer/

stream_img

Filed under: Cancer, , , , ,

Blog views to date

  • 92,118 hits

Enter your email address to subscribe to The Last Six Months and receive notifications of new posts by email.

Join 1,399 other followers

Helpful Pages, Templates etc

Recent Posts

Pages